13 August 2015 - Biogen Canada Inc. has announced the Health Canada approval of Plegridy (peginterferon beta-1a), which has been approved for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to slow the progression of disability. Plegridy offers a unique combination of demonstrated efficacy, a favourable safety profile consistent with the established interferon class, and an every two week dosing schedule.

"Plegridy is the first interferon dosed once every two weeks, which reduces the frequency of relapses and slows the progression of disability in people living with RRMS," said Dr. Marcelo Kremenchutzky, Director of the Multiple Sclerosis Clinic in London, Ontario. "Plegridy provides the safety profile we have come to expect from an interferon, with demonstrated efficacy and the added convenience of a reduced dosing schedule."

For more details, go to: http://www.newswire.ca/news-releases/health-canada-approves-plegridy-peginterferon-beta-1a-for-adults-with-relapsing-remitting-multiple-sclerosis-521732181.html